Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.

Hiroaki IkesueMoe MouriHideaki TomitaMasaki HirabatakeMai IkemuraNobuyuki MuroiShinsuke YamamotoToshihiko TakenobuKeisuke TomiiMutsushi KawakitaHironori KatohTakayuki IshikawaHisateru YasuiTohru Hashida

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)

The results of this study suggest that treatment with denosumab, age > 65 years, and tooth extraction before and after starting BMA treatments are significantly associated with developing MRONJ in patients undergoing treatment for bone metastases. However, MRONJ caused by denosumab resolves faster than that caused by zoledronic acid.

Keyphrases

patients undergoing
bone mineral density
giant cell
healthcare
combination therapy
postmenopausal women
adverse drug
electronic health record